7,978 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Acquired by Atria Investments Inc

Atria Investments Inc bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 7,978 shares of the specialty pharmaceutical company's stock, valued at approximately $288,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its holdings in shares of Supernus Pharmaceuticals by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 753,363 shares of the specialty pharmaceutical company's stock worth $27,242,000 after purchasing an additional 40,968 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in Supernus Pharmaceuticals by 219.1% in the fourth quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company's stock valued at $47,000 after acquiring an additional 870 shares in the last quarter. Proficio Capital Partners LLC bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at $408,000. Bank of New York Mellon Corp lifted its position in Supernus Pharmaceuticals by 7.3% during the fourth quarter. Bank of New York Mellon Corp now owns 399,584 shares of the specialty pharmaceutical company's stock valued at $14,449,000 after buying an additional 27,134 shares during the period. Finally, Quartz Partners LLC lifted its position in Supernus Pharmaceuticals by 3.0% during the fourth quarter. Quartz Partners LLC now owns 28,499 shares of the specialty pharmaceutical company's stock valued at $1,031,000 after buying an additional 820 shares during the period.

Remove Ads

Supernus Pharmaceuticals Stock Performance

Shares of SUPN traded up $0.08 during trading hours on Thursday, hitting $32.11. The company had a trading volume of 22,917 shares, compared to its average volume of 547,021. The firm has a fifty day moving average price of $35.90 and a 200-day moving average price of $35.11. The stock has a market capitalization of $1.79 billion, a price-to-earnings ratio of 30.00 and a beta of 0.83. Supernus Pharmaceuticals, Inc. has a 52-week low of $25.53 and a 52-week high of $40.28.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Jonathan Rubin sold 927 shares of the business's stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the transaction, the senior vice president now owns 7,853 shares of the company's stock, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Padmanabh P. Bhatt sold 9,477 shares of the business's stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the transaction, the vice president now directly owns 10,149 shares of the company's stock, valued at approximately $402,915.30. This trade represents a 48.29 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 11,104 shares of company stock valued at $440,263 in the last quarter. 9.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several brokerages have commented on SUPN. StockNews.com raised Supernus Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $36.00 price target on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.